Moving beyond atherosclerosis, PCSK9's implications in abdominal aortic aneurysm (AAA) and coronary artery disease (CAD) bring to light its viability as a therapeutic target in addressing inflammatory processes and cardiovascular risks associated with these conditions [40, 101-103]. The gene discussed is PCSK9; the disease is triple-A syndrome.